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ABSTRACT
Several compounds bearing the indolinone chemical scaffold are known to 
possess anticancer properties. For example, the tyrosine kinase inhibitor sunitinib 
is an arylideneindolin-2-one compound. The chemical versatility associated with 
structural modifications of indolinone compounds underlies the potential to discover 
additional derivatives possessing anticancer properties. Previously synthesized 
3-(2-oxoethylidene)indolin-2-one compounds, also known as supercinnamaldehyde 
(SCA) compounds in reference to the parent compound 1 [1-methyl-3(2-
oxopropylidene)indolin-2-one], bear a nitrogen-linked α,β-unsaturated carbonyl 
(Michael acceptor) moiety. Here we found that analogs bearing N-substituents, 
in particular compound 4 and 5 carrying an N-butyl and N-benzyl substituent, 
respectively, were strongly cytotoxic towards human HCT 116 colorectal and MCF-7 
breast carcinoma cells. These compounds also displayed strong thioredoxin reductase 
(TrxR) inhibitory activity that was likely attributed to the electrophilicity of the 
Michael acceptor moiety. Their selectivity towards cellular TrxR inhibition over related 
antioxidant enzymes glutathione reductase (GR), thioredoxin (Trx) and glutathione 
peroxidase (GPx) was mediated through targeting of the selenocysteine (Sec) residue 
in the highly accessible C-terminal active site of TrxR. TrxR inhibition mediated by 
indolin-2-one compounds led to cellular Trx oxidation, increased oxidative stress 
and activation of apoptosis signal-regulating kinase 1 (ASK1). These events also 
led to activation of p38 and JNK mitogen-activated protein kinase (MAPK) signaling 
pathways, and cell death with apoptotic features of PARP cleavage and caspase 3 
activation. In conclusion, these results suggest that indolin-2-one-based compounds 
specifically targeting TrxR may serve as novel drug leads for anticancer therapy.
INTRODUCTION
Due to aberrant metabolic events and abnormal 
proliferative growth phenotypes, reactive oxygen species 
(ROS) levels are commonly elevated in cancer cells 
[references cited in 1, 2]. To cope with an increase in 
intrinsic oxidative stress, cancer cells augment their 
antioxidant capacity through upregulation of antioxidant 
enzymes. In doing so, cancer cells become more dependent 
on the elevated antioxidant capacity for growth and 
survival, which makes them susceptible when oxidative 
stress is further elevated through production of more 
ROS and/or inhibition of elevated antioxidant enzymes. 
The selective targeting of cancer cells on the basis of 
different redox states between normal and tumor cells is 
therefore a feasible strategy [1, 3-6], particularly when 
it involves targeting a redox adaptive mechanism that 
confers drug resistance [2]. In this context, inhibition of 
               Research Paper
Oncotarget40234www.impactjournals.com/oncotarget
the thioredoxin (Trx) system has emerged as a promising 
redox-modulating strategy for anticancer therapy. The 
Trx system, together with the glutathione system, forms 
the two main cellular thiol antioxidant systems that 
can be targeted for anticancer therapy [7, 8]. The Trx 
system comprises Trx, thioredoxin reductase (TrxR) and 
NADPH, where Trx executes antioxidant roles directly 
by reducing protein disulfides, as well as indirectly by 
donating reducing equivalents to peroxide scavenging 
enzymes such as peroxiredoxins [9] or reductive repair 
enzymes such as methionine sulfoxide reductases [10] or 
sulfiredoxin [11]. In addition, through Trx’s involvement 
in DNA synthesis, its role in the enzymatic regulation of 
several redox-sensitive transcription factors, and its direct 
binding to and inhibition of apoptosis signal regulating 
kinase 1 (ASK1), the Trx system is highly important 
for multiple cellular aspects involving cell survival and 
proliferation [12, 13].
In carcinogenesis, several lines of evidence have 
suggested that the Trx system can support tumor growth 
and progression. Firstly, TrxR, the enzyme recycling 
oxidized Trx to its reduced form, has been found to 
be essential for tumorigenesis in mouse xenograft 
models [14]. Secondly, Trx and TrxR are found to be 
overexpressed in a number of human cancer cell lines and 
primary tumors, and their overexpression is associated 
with tumor aggressiveness, cancer drug resistance, and 
poor prognosis [15-25]. TrxR is furthermore a promising 
molecular target for anticancer therapy given that its 
inhibition may lead to directly muted activities of TrxR 
as well as downstream inhibition of components in 
the Trx pathway. TrxR is an attractive target in view of 
its druggability by virtue of the presence of an easily 
accessible selenocysteine (Sec) residue located in the 
C-terminal active center of the enzyme [26]. The selenol 
group within a Sec residue is fully ionized at physiological 
pH, making the nucleophilic selenolate anion available for 
targeting by electrophilic compounds. Among classes of 
compounds currently known to inhibit TrxR, several are 
drugs used in anticancer therapy and of these many contain 
α,β-unsaturated carbonyl (Michael acceptor) moieties that 
are perceived to target nucleophilic Sec and Cys residues 
in the C- and/or N-terminal active site of mammalian TrxR 
through Michael addition reactions [27-29].
Compounds bearing the indolin-2-one chemical 
scaffold have been the focus of several biological studies 
[30-34]. In the context of discovering anticancer agents, 
the tyrosine kinase inhibitor sunitinib indicated for 
the treatment of renal cell and gastrointestinal stromal 
tumors [35, 36] is an arylideneindolin-2-one compound. 
3-Benzylidene-indolin-2-ones are also promising 
compounds for the treatment of hepatocellular carcinoma 
and have been found to inhibit multiple tyrosine kinases 
[37]. In another study that investigated the NAD(P)
H:quinone oxidoreductase 1 (NQO1) inducing activity 
of a series of 3-benzylidene-indolin-2-ones, most of 
the test compounds were found to cause induction of 
NQO1, a cytoprotective enzyme whose upregulation 
is usually associated with chemopreventive potential 
[38]. Conversely, fewer compounds registered strong 
anti-proliferative activities [38]. Derivatives carrying 
N-substituents of indolinone compounds have not yet been 
explored for cellular effects, which was therefore the aim 
of the present study.
In our laboratory, a series of 3-(2-oxoethylidene)
indolin-2-ones were previously synthesized and 
investigated for their chemopreventive and anti-
inflammatory potential [39]. Of note, these compounds are 
also known as supercinnamaldehyde (SCA) compounds 
in reference to the parent compound 1 [1-methyl-3(2-
oxopropylidene)indolin-2-one] that is commercially 
known as supercinnamaldehyde. Among the tested 
compounds, analogs carrying N-substituents were deemed 
unsuitable candidates for use in chemopreventive and 
anti-inflammatory strategies due to their strong anti-
proliferative properties [39]. Several of the compounds 
were also found to activate the nuclear factor erythroid 
2 p45-related factor 2 (Nrf2) transcription factor [39] 
and since several Nrf2 activating compounds are 
known to target TrxR [40], we here hypothesized that 
Michael acceptor-containing indolin-2-one compounds, 
particularly those that displayed potent cytotoxicities, 
could possess TrxR inhibitory activities. In this study, 
we report the discovery of indolin-2-one compounds 
carrying N-substituents that indeed display enhanced TrxR 
inhibitory and cellular anti-proliferative activities. N-butyl 
and N-benzyl substituents yielded the most potent analogs 
that could thereby serve as promising lead compounds for 
development of novel anticancer drug therapies.
RESULTS
Indolin-2-one compounds display anti-proliferative 
and in vitro TrxR inhibitory activities
A series of analogs (structures presented in Table 1) 
containing a Michael acceptor-based 3-(2-oxopropylidene)
indolin-2-one scaffold was evaluated for cytotoxicity 
towards human-derived colorectal HCT 116 and breast 
MCF-7 carcinoma cells over a duration of 72 h. The 
compounds exhibited varied growth inhibitory and 
cytotoxic effects in both cell lines, as indicated by their 
respective GI50 and LC50 values (Table 2). HCT 116 cells 
were generally more susceptible to the compounds. Among 
the tested compounds, analogs with an R1 substituent 
more bulky than a methyl group (compounds 2-5) were 
observed to elicit greater anti-proliferative activities. 
Notably, compounds 5 and 4 bearing a benzyl and n-butyl 
R1 substituent, respectively, possessed the strongest anti-
proliferative activities (Table 2; compounds were arranged 
in ascending order of GI50 and LC50 values). Compound 6, a 
derivative bearing a methyl and a phenyl substituent at the 
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R1 and R2 position, respectively, exhibited enhanced growth 
inhibitory properties in comparison to the parent compound 
1. On the other hand, the remaining analogs containing a 
common methyl R1 group and a substituted phenyl group at 
the R2 position did not exhibit enhanced anti-proliferative 
activities in comparison to the parent compound 1.
The inhibition of recombinant mammalian TrxR 
by indolin-2-one compounds after 30 min of incubation 
in the presence of NADPH was evaluated in the in vitro 
5,5'-dithiobis(2-nitrobenzoic acid) acid (DTNB) reduction 
assay and the IC50 values are presented in Table 2. To 
illustrate the dose-dependent inhibitory activities of 
the tested compounds, the extent of TrxR inhibition by 
selected indolin-2-one compounds 1, 4, 5 and 6 over a 
range of 1-100 µM is presented in Figure 1A. Comparison 
of the IC50 values at 30 min with the GI50 values revealed 
a strong correlation between the TrxR inhibitory and 
anti-proliferative activities of the analogs for the HCT 
116 cell line (r = 0.8) whereas for the MCF-7 cell line, 
the correlation was relatively weaker (r = 0.47) (Figure 
1B). This correlation suggested that TrxR inhibition could 
potentially serve as an underlying mechanism for at least 
part of the anti-proliferative effects of these compounds. 
The effects of lead indolin-2-one compounds 4 and 5 on 
the viability of MRC-5 human normal lung fibroblasts 
were also tested and found to possess a greater LC50 value 
by approximately 2-fold (compound 4: LC50 value 9.7 ± 
0.2 µM in HCT 116 cells versus 25.5 ± 2.7 µM in MRC-5 
cells; compound 5: LC50 value 9.4 ± 0.3 µM in HCT 116 
cells versus 22.7 ± 2.4 μM in MRC-5 cells. The marginal 
selectivity of the compounds for cancer cell lines over 
normal cell types would need further work either through 
deriving more analogs bearing desirable structural features 
or utilization of cancer cell-targeted delivery approaches to 
improve selectivity.
Lead indolin-2-one compounds selectively inhibit 
cellular TrxR activity
To further probe whether the correlation between 
TrxR inhibition and cytotoxic effects (Figure 1B) could 
be casual, we next assessed whether the compounds 
were more selective for TrxR than targeting other redox 
active enzymes. Specificity of the selected indolin-2-
one compounds 1, 4, 5 and 6 towards GR and GPx was 
first evaluated in in vitro assays using pre-reduced yeast 
non-selenoprotein GR and bovine selenoprotein GPx 
enzymes. As shown in Figure 2A and 2B respectively, 
activities of yeast GR and bovine GPx were found to 
be uninhibited after 60 min incubation with the selected 
compounds. Instead, some compounds were observed to 
cause marginal elevation of GR (for compound 6) and 
GPx (for compound 4) activity. The selectivity of these 
four analogs against Trx- and GSH-related enzymes was 
Table 1: Chemical structures of 3-(2-oxoethylidene)indolin-2-one compounds investigated in this study
Compounds R1 R2 Compounds R1 R2
1* methyl methyl 11 methyl 4-isopropylphenyl
2 ethyl methyl 12 methyl 4-n-butylphenyl
3 isopropyl methyl 13 methyl 4-fluorophenyl
4 n-butyl methyl 14 methyl 3-chlorophenyl
5 benzyl methyl 15 methyl 4-chlorophenyl (E form)
6 methyl phenyl 16 methyl 2-(trifluoromethyl)phenyl
7 methyl 2-methylphenyl 17 methyl 3-(trifluoromethyl)phenyl
8 methyl 3-methylphenyl 18 methyl 4-(trifluoromethyl)phenyl
9 methyl 4-methylphenyl 20 methyl 4-chlorophenyl (Z form)
10 methyl 4-ethylphenyl
*Compound 1 is the parent compound; also commercially known as supercinnamaldehyde (SCA).
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next examined in a cellular context using HCT 116 and 
MCF-7 cells. As illustrated in Figure 3A, a shorter 10 
h treatment with compounds 1 and 6 at concentrations 
around the LC50 values in the 72 h incubations (20, 
30 and 40 µM; see Table 1) and a lethal concentration 
(50 µM) did not cause apparent inhibition of cellular 
TrxR activity. On the contrary, the more cytotoxic lead 
compounds 4 and 5 caused a decrease in TrxR activity 
in a dose-dependent manner within this time frame 
(Figure 3A). In particular, compound 5 produced a 
significant reduction in cellular TrxR activity at 40 and 
50 µM, respectively, in both HCT 116 and MCF-7 cells 
(Figure 3A). Additionally, Western blot analyses showed 
that levels of TrxR protein in lysate samples of these 
cells treated with compounds 4 and 5 were not lower 
than in cells treated with vehicle, suggesting that the 
decrease in cellular TrxR activity was due to formation 
of irreversibly inhibited enzyme species (Figure 3E). 
The cellular activities of GR, Trx and GPx, in contrast, 
were either constant or increased (Figure 3B, 3C and 
3D respectively), indicating that the indolin-2-one 
compounds were selective for TrxR inhibition. The 
increased activities could likely have been due to Nrf2 
activation, as previously found for several indolin-2-
one analogs [39]. Indeed, when wild-type (Keap1+/+) 
and Keap1-null (Keap1−/−) MEFs were treated with 
compounds 4 and 5, the Keap1−/− MEFs that had the 
Keap1 gene {Keap1 protein is a negative regulator of 
Nrf2 [41]} knocked out were not only more resistant 
to indolin-2-one-mediated TrxR inhibition (Figure 4A) 
than the Keap1+/+ MEFs (Figure 4B), but also displayed 
elevated TrxR activity when treated with compounds at 
concentrations 20 to 40 µM (Figure 4A). The results, 
which were in agreement with higher expression levels 
of Nrf2 and TrxR in the Keap1−/− MEFs than those in 
the Keap1+/+ MEFs (Figure 4C), had indicated that the 
Table 2: Anti-proliferative and TrxR inhibitory activities of indolin-2-one compounds obtained from MTT cell 
viability assay and in vitro TrxR DTNB reduction assay respectively
Compounds Cell viability TrxR inhibition
HCT 116 cells MCF-7 cells 30 min
GI50 (µM) LC50 (µM) GI50 (µM) LC50 (µM) IC50 (µM)
5 3.2 ± 0.1 9.4 ± 0.3 4.5 ± 0.6 9.6 ± 0.2 6.2 ± 1.7
4 4.5 ± 0.9 9.7 ± 0.2 6.4 ± 1.5 22.4 ± 3.6 8.6 ± 0.9
2 4.2 ± 0.5 9.7 ± 0.1 7.9 ± 1.7 25.0 ± 1.6 10.2 ± 1.8
3 5.3 ± 0.1 9.8 ± 0.1 7.1 ± 0.6 22.4 ± 0.6 15.0 ± 1.4
6 8.5 ± 0.8 27.2 ± 2.4 14.0 ± 3.7 27.1 ± 0.5 14.7 ± 3.2
8 10.4 ± 2.6 28.0 ± 1.0 14.0 ± 0.6 27.9 ± 0.6 22.5 ± 0.4
9 10.5 ± 1.2 28.6 ± 0.8 10.5 ± 0.8 28.4 ± 0.8 21.6 ± 4.4
1 11.8 ± 3.3 26.8 ± 1.2 15.1 ± 4.1 27.6 ± 0.4 22.1 ± 1.8
10 11.9 ± 1.1 28.8 ± 1.1 10.4 ± 0.6 30.4 ± 6.2 19.1 ± 0.4
13 11.9 ± 0.5 29.0 ± 1.4 12.5 ± 2.4 28.6 ± 1.2 18.7 ± 3.56
15 12.4 ± 2.8 28.6 ± 1.4 20.9 ± 3.0 92.0 ± 1.2 16.9 ± 3.4
7 12.4 ± 2.1 27.8 ± 0.8 17.3 ± 4.6 27.9 ± 1.5 19.0 ± 2.4
12 13.5 ± 2.6 26.7 ± 0.8 16.5 ± 4.0 81.2 ± 9.7 > 100
11 14.4 ± 1.8 26.7 ± 1.7 10.5 ± 1.7 27.0 ± 0.4 25.2 ± 5.4
14 15.6 ± 1.1 26.9 ± 1.5 23.0 ± 4.5 84.3 ± 5.8 18.4 ± 2.2
18 15.7 ± 1.7 90.5 ± 7.3 44.4 ± 0.1 89.8 ± 5.1 > 100
17 16.1 ± 2.2 26.2 ± 2.1 17.9 ± 0.4 89.6 ± 3.6 34.2 ± 18.2
20 16.1 ± 2.4 28.7 ± 2.4 20.4 ± 3.5 91.7 ± 2.0 15.9 ± 2.9
16 19.5 ± 1.3 27.7 ± 3.1 15.8 ± 1.0 27.7 ± 1.9 28.9 ± 0.2
Compounds were listed in descending order of their anti-proliferative activities against HCT 116 cells.
Values for 50% growth inhibition concentration (GI50), 50% lethal concentration (LC50), and 50% inhibition concentration 
(IC50), are presented as means ± SD of 3 independent experiments.
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Figure 1: In vitro effects of compounds 1, 4, 5 and 6 on recombinant rat TrxR activity and correlation of the in vitro 
TrxR inhibitory and anti-proliferative potencies of indolin-2-one compounds. A. TrxR activity was evaluated by DTNB 
reduction assay after 30 min incubation of the indicated compounds with 100 nM recombinant rat TrxR and 200 µM NADPH. All data 
points are means ± SD of at least 2 independent experiments. B. The in vitro 50% TrxR inhibition concentration (IC50) values at 30 min were 
plotted against the corresponding growth inhibition concentration (GI50) values of the tested indolin-2-one compounds obtained in HCT 116 
and MCF-7 cells. A strong and fair correlation between the TrxR inhibitory and anti-proliferative activities of the tested analogs (excluding 
outliers compounds 12 and 18) was obtained for the HCT 116 and MCF-7 cell line respectively. Calculated linear correlation coefficient r 
values are 0.80 (for HCT 116 cells) and 0.47 (for MCF-7 cells).
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Figure 2: In vitro effects of compounds 1, 4, 5 and 6 on yeast GR and bovine GPx activity. A. The activity of yeast GR (20 
nM) incubated with the indicated compounds and 200 µM NADPH for 1 h was determined by following the absorbance at 340 nm upon 
addition of GSSG. B. The activity of bovine GPx (100 nM) incubated with the indicated compounds, 20 nM yeast GR, 200 µM NADPH 
and 1 mM GSH for 1 h was determined by measuring the absorbance at 340 nm upon addition of H2O2. All data points were means ± SD 
of 2 independent experiments.
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Figure 3: Dose-dependent effects of compounds 1, 4, 5 and 6 on TrxR, GR, Trx and GPx activities in HCT 116 and 
MCF-7 cells. Lysates of HCT 116 and MCF-7 cells treated with indicated concentrations of selected SCA analogs for 10 h were assessed 
for activities of A. TrxR, B. GR, C. Trx and D. GPx. Enzyme activities were expressed as a percentage of those in DMSO-treated cells. 
All data points are means ± SD of two to four independent experiments. * Statistically significant difference (p < 0.05) in enzyme activity 
as compared to DMSO control. E. The lysates of cells treated with compound 4 and 5 as mentioned in (A)-(D) were analyzed by Western 
blotting with indicated antibodies for TrxR and Trx expression. Western blot images are representative of three independent experiments.
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increased activities of TrxR in indolin-2-one-treated 
cells were attributed to increased Nrf2 activation.
TrxR inhibition by lead indolin-2-one 
compounds leads to Trx oxidation and induction 
of ASK1-mediated apoptotic cell death
The cellular events linking TrxR inhibition by 
indolin-2-one lead compounds to cell death were examined 
in HCT 116 cells. First, the redox state of cellular Trx was 
probed using an IAA-coupled alkylation method [42]. 
This analysis had revealed time-dependent oxidation of 
Trx following treatment with compounds 4 and 5 at the 
lethal dose of 40 µM (Figure 5A), suggesting that TrxR 
inhibition caused by indolin-2-one compounds triggered 
Trx oxidation. Second, a significant dose-dependent 
elevation in cellular oxidative stress was evident within 
3 h of treatment with compounds 4 and 5, as illustrated 
using a DCF fluorescence assay (Figure 5B). Notably, 
treatment with 50 µM of compound 4 and 5 resulted in 
markedly increased DCF fluorescence as compared to that 
seen in DMSO control cells. Consistent with the observed 
increase in DCF fluorescence, treatment of HCT 116 
cells with lead compounds 4 and 5 for 5 h were found to 
cause depletion of total cellular thiols in a dose-dependent 
manner (Figure 5C). This had indicated the reactivity of 
indolin-2-one compounds to thiols and the more oxidized 
state of the cells as compared to untreated cells.
One mechanism through which Trx can exert 
anti-apoptotic effects involves suppression of ASK1-
dependent apoptosis through a direct inhibitory protein-
protein interaction between reduced Trx and ASK1 [43]. 
This interaction is dependent on the redox state of Trx, 
with oxidation of Trx resulting in the dissociation of 
the Trx-ASK1 complex, which was therefore examined 
next. Indeed, Trx immunoprecipitation from lysates 
of ASK1-overexpressing HCT 116 cells treated with 
compound 4 revealed a dose-dependent decrease 
in the amount of ASK1 bound to Trx1 (Figure 5D). 
This corresponded to an increased activation of the 
ASK1 downstream mitogen-activated protein kinases 
(MAPKs) targets p38 and JNK [phosphorylated p38 
(p-p38) and JNK (p-JNK)] (Figure 5E). Finally, 
ASK1-dependent activation of p38 and JNK MAPK 
pathways triggered apoptotic cell death, as evident from 
a dose-dependent appearance of apoptotic markers such 
as cleaved forms of PARP and caspase 3 (Figure 5F). 
Of note, a higher concentration (50 µM) of the more 
cytotoxic compound 5 brought about lower activation 
of PARP and caspase-3 (Figure 5F), which could have 
been due to excessive oxidative stress instead leading 
to necrosis.
Figure 4: Dose-dependent effects of compounds 4 and 5 on TrxR activity in wild-type and Keap1-null MEFs. Lysates 
of A. Keap1-null (Keap1−/−) and B. wild-type (Keap1+/+) MEFs treated with indicated concentrations of compounds 4 and 5 for 5 h were 
assessed for TrxR activities. C. Lysates of untreated Keap1−/− and Keap1+/+ MEFs were analyzed by Western blotting with indicated 
antibodies for Nrf2 and TrxR expression. Western blot images are representative of three independent experiments.
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Lead indolin-2-one compounds inhibit TrxR 
irreversibly and target the penultimate 
selenocysteine residue in the C-terminal active site
The mode of TrxR inhibition by lead indolin-2-
one compounds was examined in more detail. Firstly, 
compounds 4 and 5 were evaluated as substrates of 
TrxR. As shown in Figure 6A, negligible increase in the 
rate of NADPH oxidation was observed upon addition 
of the compounds, as compared to that of DMSO-
treated enzyme. On the contrary, the rate of NADPH 
consumption of recombinant TrxR treated with juglone, 
a known TrxR substrate [44], was markedly increased 
(Figure 6A). This indicated that the compounds were 
not TrxR substrates. Secondly, the reversibility of the 
TrxR inhibition by compounds 4 and 5 was investigated 
by treating NADPH-reduced recombinant TrxR with 
20 µM of the compounds for 30 min to fully abolish its 
Figure 5: Effects of lead indolin-2-one compounds on Trx oxidation, Trx-ASK1 interaction and apoptosis induction in HCT 
116 cells. A. Top panel: time-dependent Trx oxidation caused by treatment with indolin-2-one compounds. Lysates of cells treated with compound 
4 or 5 (40 µM) for 4, 8 and 14 h were collected in guanidine-containing lysis buffer containing 50 mM IAA and subjected to native PAGE and 
Western blot analysis using Trx antibody. Bottom panel: mean densitometric intensities of reduced and oxidized Trx protein bands for each treatment 
group (n = 3). B. Dose-dependent increase in DCF fluorescence in cells treated with indolin-2-one compounds. Following a 3-h treatment with 
compound 4 or 5 at indicated concentrations, HCT 116 cells were incubated with 10 µM carboxy-H2DCFDA in the dark for 45 min at 37°C. 
Fluorescence was then measured at 530 nm. * Statistically significant difference (p < 0.05) as compared to DMSO control (n = 3). C. Effects of 
indolin-2-one compounds on total cellular thiol levels. Following a 4-h treatment with compound 4 or 5, total thiol content in HCT 116 cells was 
assessed. * Statistically significant difference (p < 0.05) as compared to DMSO control (n = 3). D.  Effects of indolin-2-one compound on Trx-ASK1 
interaction. Lysates from ASK1-transfected HCT 116 cells after 2-h treatment with DMSO or compound 4 were subjected to immunoprecipitation 
using anti-human Trx antibody. Immunoprecipitates and aliquots of the cell lysates were subjected to SDS-PAGE and Western blot analysis using 
the indicated antibodies. E. Dose-dependent effects of indolin-2-one compounds on MAPK activation. Lysates of cells after 3 h of treatment with 
DMSO, compound 4 or 5 were collected and subjected to SDS-PAGE and Western Blot analysis of levels of phosphorylated and total JNK and p38. 
F. Dose-dependent induction of apoptosis, indicated by presence of cleaved caspase 3 (17/19 kDa) and PARP (89 kDa) in HCT 116 cells treated with 
compound 4 or 5 for 10 h. All Western blot images shown are representative of three independent experiments.
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Figure 6: Effects of lead indolin-2-one compounds on NADPH oxidase activity of recombinant rat TrxR, irreversibility 
of TrxR inhibition, and juglone and DTNB reduction by TrxR. A. Upon incubation of recombinant rat TrxR (15 nM) with 
250 µM NADPH and juglone, compound 4 or 5 at indicated concentrations, consumption of NADPH was measured at 340 nm for 
20 min. Results represent the mean ± SD of three independent experiments. B. Investigation of the irreversibility of TrxR inhibition 
by compounds 4 and 5. Recombinant rTrxR (0.9 µM) was incubated with 20 µM of the lead compounds and 200 µM NADPH for 30 
min. Excess compound was removed by desalting the protein sample using an NAP-5 column. TrxR activity was determined by DTNB 
reduction assay at indicated timepoints before and after desalting. Results shown are representative of two independent experiments. 
C. Effects of lead indolin-2-one compounds on dose-dependent juglone reduction and DTNB reduction by TrxR. Recombinant rat TrxR 
(15 nM) was reduced by 250 µM NADPH and incubated with indicated concentrations of compound 4 or 5 for 15 min. Following the 
incubation, DTNB reduction or juglone reduction were measured. For DTNB reduction, 50 µl of 8.75 µM DTNB solution in TE buffer 
was added and DTNB reduction was measured at 412 nm for 2 min. For juglone reduction, 100 µl of 300 µM juglone solution in TE 
buffer was added and NADPH consumption at 340 nm was monitored for 5 min. The results were expressed as % of TrxR juglone 
reduction or DTNB reduction activity of drug-treated sample over that of DMSO-treated sample. Results are presented as means ± SD 
of three independent experiments.
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activity, followed by desalting to remove any excess of 
unbound compound. TrxR activity could not be recovered 
within 2 h of post-desalting (Figure 6B), suggesting that 
compounds 4 and 5 were irreversible inhibitors of TrxR.
Several inhibitors of mammalian TrxR have been 
shown to cause formation of selenium compromised 
thioredoxin reductase apoptotic proteins (SecTRAPs), 
which are incapable of supporting Trx reduction 
due to targeting of the Sec residue in the C-terminal 
active center, whereas an N-terminal active center 
remains functional allowing for an NADPH oxidase-
like activity of the enzyme to persist [45]. Generation 
of SecTRAPs can thereby lead to enhanced ROS 
production, which may trigger a mixture of apoptotic 
and necrotic cell death due to excessive oxidative stress 
[45]. To investigate whether the compounds produced 
SecTRAPs from TrxR, redox cycling with juglone by 
recombinant TrxR inhibited by lead indolin-2-one 
compounds was studied, which is a model assay for 
SecTRAPs properties [45]. The results showed that 
juglone reduction was more preserved than DTNB 
reduction upon inhibition by compounds 4 and 5 
(Figure 6C), indeed suggesting formation of SecTRAPs. 
We next investigated whether the compounds targeted 
the Sec residue in the C-terminal active center of 
mammalian TrxR using an alternative N-(biotinoyl)-
N’-(iodoacetyl)-ethylenediamine (BIAM) labeling 
assay [46]. In this assay, recombinant TrxR incubated 
with 200 µM NADPH and 20 µM of compound 4 or 5 
for specified timepoints was next probed with BIAM at 
pH 6.5, which allows preferential alkylation of reactive 
Sec residues but not Cys residues due to the difference 
in pKa between Sec (pKa 5.2) and Cys (pKa 8.0). 
Treatment with compounds 4 or 5 resulted in a decrease 
in TrxR activity over time (top panel of Figure 7), 
which correlated with a prevention of BIAM alkylation 
(bottom panel of Figure 7).
DISCUSSION
We previously reported that hydroxy and fluorine 
substitutions render strong TrxR inhibitory character 
to cinnamaldehydes and compounds containing a 
1,5-diphenyl-pent-1-en-3-one (DDPen) or 1,3-diphenyl-
prop-1-en-3-one (DPPro; also known as chalcone) 
pharmacophore [47, 48]. In the present study, the 
evaluated indolin-2-one compounds contain the 
3-(2-oxopropylidene)indolin-2-one backbone, which 
possesses two conjugated α,β-unsaturated carbonyl 
groups as Michael acceptors. We found a majority of the 
compounds displayed a good correlation between anti-
proliferative activities toward two human cancer cell 
lines and TrxR inhibition, which has several important 
implications.
It is notable that several of the indolin-2-one 
compounds studied here are also Nrf2 inducers [39], 
which agrees well with the notion that TrxR inhibition 
can lead to Nrf2 activation, as recently discussed 
elsewhere in further detail [40]. Our assessments of the 
compounds’ effects on TrxR, Trx, GR and GPx had both 
demonstrated target selectivity, as only TrxR was among 
these enzymes inhibited by the compounds in vitro, and 
Nrf2 activation, as the cellular activities of these other 
Nrf2-induced enzymes were increased in a cellular 
context together with inhibition of TrxR.
As the indolin-2-one compounds irreversibly 
inhibited TrxR, this suggested that covalent binding 
occurred between the compounds and a nucleophilic 
Sec, or possibly Cys residue in TrxR. The sustained 
juglone reduction activity of the inhibited enzyme, 
as well as the BIAM assay results, were findings that 
would be compatible with preferential targeting at the 
Sec residue of TrxR. This effect can also explain the 
cytotoxicity of these compounds, most likely being due 
to a rapidly triggered oxidative stress resulting in both 
specific signaling events leading to apoptosis as well as 
necrotic cell death.
We propose that oxidative stress upon indolin-
2-one-mediated TrxR inhibition can be triggered via 
several specific pathways. Firstly, as inferred from 
results obtained from the juglone reduction assay, 
treatment with compounds 4 and 5 can result in 
formation of SecTRAPs, thereby converting TrxR to 
a prooxidant NADPH oxidase. Indeed, as it had been 
observed previously for 1-chloro-2,4,-dinitrobenzene 
(DNCB) or cisplatin, the formation of SecTRAPs in 
cells can result in rapid induction of oxidative stress 
leading to cell death [45, 49]. Secondly, increased 
levels of oxidized Trx (as a result of TrxR inhibition) 
should prevent Trx of providing reducing equivalents 
to peroxiredoxins, which will further aggravate the 
oxidative stress as a result of impaired antioxidant 
defense. Furthermore, our results were compatible 
with the effects of increased Trx oxidation leading 
to dissociation of Trx-ASK1 complexes, followed by 
activation of ASK1 and its downstream JNK and p38 
MAPK signaling pathways leading to apoptotic cell 
death induction [43, 50]. Indeed, dissociation of the 
ASK1-Trx complex in HCT 116 cells upon treatment 
with compound 4 was observed in our study. As 
treatment with lead indolin-2-one compounds also 
resulted in a dose-dependent increase in levels of 
activated p38 and JNK, this showed involvement of 
these two MAPK signaling cascades in mediating cell 
death induced by these compounds.
In summary, Michael acceptor-based com-
pounds are a class of TrxR inhibitors that possess 
electrophilicities to target nucleophilic Sec and Cys 
residues in the active sites of mammalian TrxR. Examples 
of several reported TrxR inhibitors that bear a Michael 
acceptor moiety [44, 47, 51-56] are illustrated in Figure 
8. This study has evaluated a series of Michael acceptor-
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Figure 7: Investigation of the interaction of lead indolin-2-one compounds with the Sec residue in the C-terminal active 
center of TrxR. Recombinant rat TrxR (0.9 µM) was incubated with 20 µM of the lead compounds and 200 µM NADPH. At indicated 
timepoints, an aliquot of enzyme mixture was drawn for TrxR activity measurement by DTNB reduction assay and BIAM labelling at pH 
6.5. Top panel: time course of TrxR enzyme activity; bottom panel: horseradish peroxidase (HRP)-conjugated streptavidin detection of 
BIAM labeling of free selenol at pH 6.5 at various incubation times. Results presented are representative of three independent experiments.
Figure 8: Examples of Michael acceptor moiety-containing compounds reported to possess TrxR inhibitory activities. 
Compounds include nature-inspired gambogic acid [51], ortho-substituted cinnamaldehydes such as 2-benzoyloxycinnamaldehyde (BCA) 
[47], curcumin [52], flavonoids myricetin and quercetin [53], chalcone-containing xanthohumol [54], quinone compounds juglone [44] and 
shikonin [55], as well as quinol compound PMX464 [56].
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based indolin-2-one compounds and identified lead 
compounds 4 and 5 carrying a N-butyl and N-benzyl 
substituent, respectively, to display the strongest 
TrxR inhibitory and anti-proliferative activities. Their 
selectivity towards inhibition of cellular TrxR activity 
was mediated through targeting the Sec residue in 
the enzyme’s C-terminal active site. Mechanistically, 
the cytotoxicities of these lead indolin-2-one analogs 
were mediated at least in part through TrxR inhibition 
and Trx oxidation, followed by ASK1-dependent 
activation of p38 and JNK MAPK signaling pathways 
(summarized in Figure 9). Importantly, this study has 
provided experimental evidence attesting that appropriate 
structural modifications to compounds bearing the 
indolinone chemical scaffold, particularly substitutions 
at the nitrogen atom, can yield derivatives that possess 
specific TrxR inhibitory activity as leads for anticancer 
drug development.
Figure 9: A summary of cellular events resulting from TrxR inhibition caused by treatment with indolin-2-one 
compounds. TrxR inhibition by indolin-2-one compounds led to formation of SecTRAPs and Trx oxidation. SecTRAPs lacking Trx 
reducing activity of TrxR could lead to enhanced ROS production and trigger a mixture of apoptotic and necrotic cell death. Trx 
oxidation further led to dissociation of ASK1 from Trx(reduced)-ASK1 complexes, followed by ASK1-dependent activation of MAPK 
signaling pathways, resulting in cell death.
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MATERIALS AND METHODS
Materials, chemicals and cell culture
Recombinant rat TrxR was prepared as previously 
described [57]. Recombinant human Trx (rhTrx1) and 
anti-human Trx antibody were obtained from IMCO 
Corporation (Stockholm, Sweden). Iodoacetamide (IAA), 
yeast glutathione reductase (GR), bovine glutathione 
peroxidase (GPx), glutathione disulfide (GSSG), 
reduced glutathione (GSH) and trypsin of proteomics 
grade were purchased from Sigma. 5-(and-6)-carboxy-
2’,7’-dichlorodihydrofluorescein diacetate (carboxy-
H2DCFDA), BIAM and HRP-conjugated streptavidin 
were from Molecular Probes and bovine insulin was 
from Gemini Bio-Products. Antibodies against Nrf2, 
full-length and cleaved caspase 3, full-length and cleaved 
poly (ADP)-ribose polymerase (PARP), JNK, phospho-
JNK (Thr183/Tyr185), p38 and phospho-p38 (Thr180/
Tyr182) were from Cell Signaling Technology, while 
those specific for human TrxR1, ASK1 and β-actin and 
HRP-conjugated secondary antibodies were from Santa 
Cruz Biotechnology. Human-derived colon HCT 116 
and MCF-7 breast carcinoma cells were maintained in 
RPMI 1640 medium, MRC-5 normal lung fibroblasts 
in MEM and wild-type (Keap1+/+) and Keap1−/− MEFs 
were cultured in IMDM containing epidermal growth 
factor (EGF; 1 µg per 100 ml medium). All media were 
supplemented with 10% fetal bovine serum, 100 units/
ml penicillin and 100 µg/ml streptomycin. The cells were 
incubated at 37ºC in an humidified atmosphere of 95% 
air and 5% CO2. Indolin-2-one compounds 1 to 20 were 
previously synthesized and were all at least 95% pure as 
assessed by HPLC-MS and 1H NMR [39]. They were 
kept as 50 mM DMSO stocks at -20°C and diluted fresh 
in DMSO or culture medium to the final concentrations 
immediately before all experiments.
Cell viability assay
HCT 116 and MCF-7 cells were seeded in 96-well 
plates at a density of 1 x 104 cells/well and allowed to grow 
for 20-24 h before addition of test compounds. DMSO 
stocks of indolin-2-one compounds were serially diluted in 
medium each time an assay was performed. Cell viability 
was determined at the time of compound addition (time 
0) and after 72 h of compound treatment by reduction 
of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) by dehydrogenases in viable cells. MTT 
was added into each well (final concentration 400 µg/
ml) and the plates were incubated for 4 h at 37°C. The 
supernatants were aspirated and upon solubilization of 
the formed formazan crystals in DMSO:glycine buffer pH 
10.5 (ratio 4:1), absorbance at 550 nm was measured. 50% 
growth inhibition concentrations (GI50) and 50% lethal 
concentrations (LC50) values were calculated.
Determination of recombinant rat TrxR activity 
by DTNB reduction assay
In a volume of 100 µl of 50 mM Tris-HCl pH 7.5, 2 
mM EDTA buffer (TE buffer), compounds of concentrations 
1-100 µM were incubated with 100 nM recombinant rat 
TrxR and 200 µM NADPH at room temperature in 96-well 
plates for 30 and 60 min. The incubation was terminated 
by addition of 100 µl per well of 10 mM DTNB, 200 µM 
NADPH solution in TE buffer and immediately followed 
by measurement of linear increase of absorbance at 412 nm 
for the initial 2 min using the VersaMax microplate reader 
(Molecular Devices). The results were expressed as % of 
TrxR activity of drug-treated sample over that of DMSO 
control. The 50% inhibition concentration (IC50) values 
were calculated.
Determination of juglone reduction by 
recombinant rat TrxR
The assay, designed to determine the ability of 
mammalian TrxR to reduce juglone at the N-terminal 
active center, was performed as described previously [44, 
45]. Briefly, 2 µl of diluted DMSO stocks of compounds 4 
and 5 (final concentrations 1-100 µM) were incubated in 
198 µl of 15 nM recombinant rat TrxR, 250 µM NADPH 
and 0.1 mg/ml BSA in TE buffer at room temperature 
in 96-well plates for 15 min. 100 mM stock solution of 
juglone in DMSO was prepared fresh for each experiment 
and diluted in TE buffer to a 300 µM working solution. 
The incubation was terminated by the addition of 100 µl 
of 300 µM juglone solution (final concentration 100 µM), 
and NADPH consumption was monitored at 340 nm for 
5 min using the VersaMax microplate reader. The linear 
decrease in NADPH absorbance was used for calculating 
juglone reduction activity. The results were expressed 
as % of TrxR juglone reduction activity of drug-treated 
sample over that of DMSO-treated sample.
The experiments were performed at the same 
time with a corresponding DTNB reduction assay as 
described above with modifications so as to keep the 
experimental parameters and conditions similar to those 
in the juglone reduction assay. Performing the DTNB 
reduction assay together with the juglone reduction assay 
ensured that any amount of TrxR inhibition registered in 
each assay could be directly cross-compared with each 
other at the same time. Following 15 min incubation 
with compound 4 or 5, 50 µl of 8.75 µM DTNB solution 
(final concentration 1.75 µM) was added to each well 
and DTNB reduction was measured at 412 nm for 2 min.
Determination of NADPH oxidase activity of 
recombinant rat TrxR
In a volume of 198 µl of 15 nM recombinant rat 
TrxR and 250 µM NADPH in TE buffer, 2 µl of diluted 
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DMSO stocks of juglone and compounds 4 and 5 was 
added to final concentrations of 8 µM (for julgone) and 
100 µM (for compounds 4 and 5). The consumption of 
NADPH was immediately monitored at 340 nm for 20 
min using the VersaMax microplate reader. The linear 
decrease in NADPH absorbance was used for calculating 
NADPH consumption and expressed as % of activity of 
drug-treated sample over that of DMSO-treated sample.
Preparation of cell lysates and Western blot 
analysis
Cells were seeded onto 100 mm or 60 mm culture 
plates and upon reaching ~70% confluency, they were 
subjected to drug treatment for indicated durations. Pellets 
of compound-treated or DMSO control cells comprising 
both attached and floating cells were collected and lysed in 
lysis buffer (25 mM Tris-HCl pH 7.5, 100 mM NaCl, 2.5 
mM EDTA, 2.5 mM EGTA, 20 mM NaF, 1 mM Na3VO4, 
20 mM sodium β-glycerophosphate, 10 mM sodium 
pyrophosphate, 0.5% Triton X-100) with freshly added 
protease inhibitor cocktail (Roche Diagnostics). Prior to 
being used in Western blot analysis and/or cellular TrxR, 
GR, Trx and GPx activity determination, lysates were 
precleared by centrifugation and protein concentrations 
were determined using a modified Bradford assay (Bio-
Rad Laboratories) as described in the manufacturer’s 
manual. This procedure for collecting whole cell lysate 
was used for all experiments except for the Trx-redox 
state determination experiment. Equal amounts of protein 
(50 µg) in each lysate sample were separated by SDS-
PAGE, followed by electroblotting onto nitrocellulose 
membranes. Electroblotted proteins on membranes were 
probed with a primary antibody and subsequently by a 
secondary antibody conjugated to HRP.
Determination of TrxR and Trx activity in cell 
lysates by insulin reduction assay
Freshly collected cell lysates were used for 
measurement of activity of cellular Trx and TrxR. To 
measure TrxR activity, in each well of a 96-well plate, 25 
µg of cell lysate was incubated in a final volume of 50 µl 
containing 85 mM Hepes (pH 7.6), 0.3 mM insulin, 10 
µM rhTrx1, 2.5 mM EDTA and 660 µM NADPH for 40 
min at 37°C. Controls containing lysates and all reaction 
reagents except rhTrx1 for each lysate sample were also 
set up. 200 µl of 1 mM DTNB in 6 M guanidine-HCl, 
200 mM Tris-HCl pH 8.0 solution was added to quench 
the reaction. The amount of free thiols generated from 
insulin reduction was determined by DTNB reduction 
at 412 nm using the VersaMax microplate reader. To 
measure Trx activity, procedures were carried out similar 
to those for determining cellular TrxR activity, except 
that the cell lysates were incubated for 20 min with 300 
nM recombinant rat TrxR in place of rhTrx1. Controls 
containing lysates and all reaction reagents except 
recombinant rat TrxR for each lysate sample were also set 
up. For each sample, Trx or TrxR activity was calculated 
as the absorbance at 412 nm subtracted from that of the 
corresponding control and expressed as a percentage of the 
activity measured in DMSO-treated cells.
Determination of yeast GR activity and GR 
activity in cell lysates by glutathione reduction 
assay
To determine in vitro yeast GR activity, 
compounds of concentrations 1-100 µM were incubated 
with 20 nM yeast GR and 200 µM NADPH in a volume 
of 100 µl phosphate buffer (0.1 M sodium phosphate, 
2 mM EDTA pH 7.5) for 1 h at room temperature. 
At the end of the incubation, 100 µl of 1 M GSSG 
(final concentration 500 µM) and 200 µM NADPH 
in phosphate buffer was added to each well. NADPH 
consumption was monitored by measurement of 
absorbance at 340 nm using the VersaMax microplate 
reader. The results were calculated based on decrease 
in absorbance in the initial 90 s and expressed as a 
percentage of the enzyme activity of the DMSO-treated 
sample. For determination of cellular GR activity, 25 
µg of cell lysate was mixed with a solution of GSSG 
and NADPH in phosphate buffer to a final volume of 
200 µl (final GSSG and NADPH concentrations 1 mM 
and 200 µM respectively). The enzyme activity was 
determined by measuring the decrease in absorbance 
at 340 nm for 10 min at 37°C and expressed as a 
percentage of the enzyme activity of that of the DMSO-
treated sample.
Determination of bovine GPx activity and GPx 
activity in cell lysates by GPx activity assays
For determination of in vitro bovine GPx activity, 
compounds of concentrations 1-100 µM were incubated 
with 100 nM bovine GPx, 20 nM yeast GR, 1 mM GSH 
and 200 µM NADPH in a volume of 100 µl phosphate 
buffer (0.1 M sodium phosphate, 2 mM EDTA pH 7.5) for 
1 h at room temperature. H2O2 solution in phosphate buffer 
was added to initiate the reaction (final concentration 1.5 
mM). NADPH consumption was monitored at 340 nm 
using the VersaMax microplate reader. The cellular GPx 
activity was determined similarly except lysates of HCT 
116 and MCF-7 cells (25 µg protein) were used instead of 
bovine GPx. The results were calculated based on decrease 
in absorbance in the initial 3 min and presented as % of 
GPx activity of drug-treated sample over that of DMSO-
treated sample.
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Determination of total cellular thiols
HCT 116 cells were seeded in 6-well plates and 
allowed to grow to 70-80% confluency. They were treated 
with compounds 4 and 5 (20, 30, 40 or 50 µM) for 4 h, after 
which collected lysates were used fresh for total cellular 
thiol determination. Briefly, in each well of a 96-well plate, 
10 µl of each lysate sample was mixed with 90 µl of 1 mM 
DTNB in 6 M guanidine-HCl, 200 mM Tris-HCl pH 8.0. 
Absorbance readings measured at 412 nm were matched 
against a calibration plot obtained from a series of serially 
diluted GSH solutions (known concentrations in µM) in 50 
mM Tris-HCl, 2 mM EDTA pH 7.5. The calculated total 
thiol content, normalized to per mg of proteins present 
in each lysate sample of compound-treated cells, was 
expressed as a percentage over that in DMSO-treated cells.
Immunoprecipitation
HCT 116 cells were seeded in 60 mm plates and upon 
reaching 40% confluency, they were transfected with 1.5 µg 
of pCMV-SPORT6-ASK1 per plate. When the transfected 
cells reached ~70% confluency, they were treated with 
DMSO or compound 4 at indicated concentrations for 4 h 
and lysates were collected for immunoprecipitation set-up. 
For each lysate sample, a volume containing 1 mg of protein 
was mixed with 1.5 µg of anti-Trx antibody coupled to 20 
µl of protein G-sepharose (GE Healthcare) and tumbled 
at 4°C for 2 h. The G-sepharose beads were washed three 
times in a cold washing buffer containing 20 mM Tris (pH 
7.5), 0.5 M NaCl and 1 mM EGTA and once in a buffer 
containing 50 mM Tris (pH 7.5). The immunoprecipitated 
proteins were denatured in SDS sample buffer containing 
5% β-mercaptoethanol and subjected to SDS-PAGE and 
Western blotting.
Determination of Trx redox state in cells
The redox state of cellular Trx was assessed as 
previously described [42]. HCT 116 cells were seeded 
in 60 mm plates and allowed to grow to 70% confluency. 
Compounds 4 or 5 were then added to the cells for 4, 8 or 14 
h. Lysates were collected in lysis buffer (50 mM Tris-HCl 
pH 8.3, 2 mM EDTA, 6 M guanidine HCl, 0.5% Triton-X, 
50 mM IAA). The lysates were incubated in the dark for 
30 min at room temperature, sonicated briefly, and finally 
passed through a MicroSpin G-25 column (GE Healthcare) 
to remove guanidine and unreacted IAA. The desalted lysates 
were subjected to native PAGE, followed by transfer of 
separated proteins onto nitrocellulose membranes for Western 
blot analysis using anti-Trx antibody.
ROS determination
Oxidative stress was assessed through estimating 
the level of ROS using the H2DCFDA assay [58] with 
modifications. Briefly, HCT 116 cells were seeded in 
6-well plates and incubated for 24-48 h at 37°C till 70-
80% confluency. They were treated with H2O2 (200 µM) or 
compounds 4 and 5 (20, 30, 40 or 50 µM) for 3 h. Following 
treatment, cells were washed with PBS and incubated with 
10 µM carboxy-H2DCFDA in PBS at 37°C in the dark for 
45 min to allow reaction between taken up H2DCF and ROS. 
The cells were collected, washed with cold PBS, pelleted, 
resuspended in 200 µl of PBS and transferred to wells in a 
96-well black fluorescence plate. The fluorescence intensities 
were measured at an excitation wavelength of 485 nm and 
an emission wavelength of 530 nm using a Tecan Infinite 
M200 Pro microplate reader. The results were expressed as a 
percentage of fluorescence intensities measured in drug-treated 
cells over those produced in DMSO-treated cells.
BIAM labeling assay
To assess whether the Sec residue in mammalian TrxR 
was susceptible to indolin-2-one compounds, biotin labeling 
through BIAM alkylation of the free selenol at pH 6.5 in 
recombinant rat TrxR was performed using a previously 
described method with modifications [46]. A 100 µM 
BIAM stock solution in 100 mM Tris-HCl, 1 mM EDTA, 
pH 6.5 was prepared fresh for each experiment. NADPH-
reduced recombinant rat TrxR (0.9 µM) was incubated with 
compound 4 or 5 (20 µM) or DMSO vehicle in 50 mM Tris-
HCl, 1 mM EDTA, pH 7.5, and 200 µM NADPH at 37°C. 
At indicated timepoints, a 3 µl aliquot was withdrawn and 
mixed with 20 µM BIAM solution in 100 mM Tris-HCl, 1 
mM EDTA, pH 6.5 for 15 min at 37°C to allow selective 
alkylation of free Sec residues. The reaction was quenched 
by adding freshly prepared IAA solution (final concentration 
50 mM). The samples were then denatured in SDS sample 
buffer, boiled and subjected to SDS-PAGE and Western 
blotting. The biotin was detected by HRP-conjugated 
streptavidin using the enhanced chemiluminescence system. 
Membranes were stripped with stripping buffer (0.15 M 
glycine, pH 2.5, 0.4% SDS) and reprobed with polyclonal 
anti-rat TrxR1 antibody purified from rabbit antiserum 
against rat liver TrxR1 [59]. At each timepoint, 15 µl of 
compound-treated  TrxR mixture was also removed for TrxR 
activity determination using the DTNB assay.
Statistical and densitometric analysis
Numerical data are presented as means ± SD of 
different determinations. Student’s t-test analysis was 
performed to compare means between control and 
treatment groups. ImageJ software (NIH) was used for 
quantification of intensities of Western blot bands.
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